Insider buying last 90 days
$1.00Min 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 12 | Albert Bourla Chairman & CEO | Purchase | $1.00M |
From Form 4 filings, dated to when each was filed.
Gekko Brief
AI summaryNov 4 closePfizer's stock moved higher this week after third-quarter results showed revenue of $16.58 billion and adjusted EPS of $0.87, beating consensus estimates of $0.74. The company raised its full-year 2026 guidance for the second time, now projecting $62 billion to $64 billion in sales and adjusted EPS of $2.95 to $3.05, citing operational growth of 7% in its non-COVID portfolio and 32% growth in launched and acquired products. Separately, Argus raised its price target on Pfizer to $40 while maintaining a positive view of the company's diversified portfolio spanning oncology, immunology, rare disease and vaccines. United Therapeutics also agreed to pay $525 million to eliminate future royalty obligations to Pfizer on ralinepag, an experimental pulmonary arterial hypertension treatment currently under FDA review.
Pfizer closed at $30.79, up 2.6%, sitting above both its 50-day average of $28.68 and 200-day average of $26.87. The GekkoIndex reads 46.3, placing the stock in the Neutral zone, down 6.4 over five days. Price sits 4.1% below Gekko Fair Value of $32.11, near its 52-week high of $31.06.
The next earnings date falls on 2 February 2027, outside a typical 20-trading-day window. Smart money activity over the past 90 days includes one insider purchase and two Congressional buys with no sales. Seasonality over the next 20 trading days has averaged 4.4% across 5 years, rising in 3 of them. Analyst consensus stands at 8 buy, 13 hold and 1 sell ratings, with a consensus target of $29.26.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Pfizer price vs fair value
Close $30.79200-day averageGekko Fair Value $32.11
Pfizer quick facts
- Market cap
- $175.5B
- P/E ratio
- 40.4
- Forward P/E
- 10.5
- EPS, TTM
- $0.76
- Revenue, TTM
- $63.70B
- Profit margin
- 6.8%
- Dividend yield
- 5.64%
- Beta
- 0.30
- Volume
- 46.66M avg 31.54M
- 1-year return
- +24.9%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.5%
- 50-day average
- $28.68
- 200-day average
- $26.87
- Next earnings
- Feb 2
- Shares outstanding
- 5.70B
Pfizer swing-trade checklist
Pfizer scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $30.79 is above the 50-day ($28.68) and 200-day ($26.87) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
46.3, Neutral
Reading 46.3 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.1% below
Price is within 5% of Gekko Fair Value (4.1% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase; Congress 2 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 89 days
Next report Feb 2, 2027, 89 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.4% on average
From this point in the calendar, the next 20 trading days averaged +4.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Pfizer stock chart and price history
Pfizer closed at $30.79 on Nov 4, 2026, +24.9% over the past year, inside a 52-week range of $23.62 to $31.06.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +12.0%
- 3 months
- +17.5%
- 6 months
- +16.1%
- 1 year
- +24.9%
The full PFE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PFE in Gekko
Follow Pfizer through every session
Put PFE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PFE in GekkoFree for 7 days. No credit card required.
About Pfizer
Pfizer develops, manufactures and sells medicines and vaccines across a broad range of health conditions. Its work spans heart and women's health treatments, biologic and small-molecule drugs, immunotherapies, and biosimilars, with brands such as Eliquis, Ibrance, Xtandi and Retacrit among its recognized names. The company is also known for Paxlovid, its oral COVID-19 treatment, and for vaccines including Comirnaty and the Prevnar line, which cover diseases such as pneumococcal and meningococcal infection and tick-borne encephalitis.
Beyond its own branded products, Pfizer runs a contract manufacturing arm and produces biosimilars for autoimmune and inflammatory disorders, alongside treatments for rare conditions like amyloidosis and hemophilia. Its customers include wholesalers, hospitals, clinics, pharmacies, government bodies and individual medical practices, and it works with partners such as Bristol-Myers Squibb, BioNTech and Merck KGaA on various programs.
Founded in 1849 and headquartered in New York, New York, Pfizer's shares are listed on the NYSE under the ticker PFE.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- pfizer.com
Pfizer GekkoIndex: the smart money zone
Pfizer’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.3, in the Neutral zone, down 6.4 points over five sessions.
46.3Neutral
Down 6.4 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.4% | +1.4% | ||
| Accumulation | 226 | +0.7% | +1.2% | ||
| Neutral (current zone) | 411 | −0.1% | −0.1% | ||
| Distribution | 18 | −2.5% | −5.1% | ||
| Selling | 1 | Too few readings yet | |||
Average PFE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PFE price, zone by zone.Track PFE in Gekko
Is Pfizer stock overvalued? Gekko Fair Value
Pfizer trades 4.1% below Gekko Fair Value of $32.11, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Pfizer shares are worth, recalculated every trading day.
$32.11
Gekko Fair Value, Nov 4, 2026
4.1% below fair value · About fair value
At the end of Aug 2026 the price was 10.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PFE in Gekko
Pfizer insider and Congress trading
Insiders filed 1 open-market purchase in Pfizer worth $1.00M, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 25 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 11 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Pfizer has been buying back its own shares.
- Bought back, quarter ended Apr 3, 2022
- $2.00B
- As a share of market cap
- 1.14%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PFE.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Pfizer earnings: next date and track record
Pfizer reports on Feb 2, 2027 (89 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 2, 2027
89 days away
- EPS estimate
- $0.72
- Revenue estimate
- $17.01B
8 of 8reports beat the EPS estimate
±1.7%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 3, 2026 | $0.87 est $0.74 | $16.58B est $15.85B | +0.4% |
| Aug 4, 2026 | $0.77 est $0.68 | $15.03B est $14.40B | +3.1% |
| May 5, 2026 | $0.75 est $0.72 | $14.45B est $13.84B | +0.9% |
| Feb 3, 2026 | $0.66 est $0.57 | $17.56B est $16.85B | +0.5% |
| Nov 4, 2025 | $0.87 est $0.63 | $16.65B est $16.50B | −0.2% |
| Aug 5, 2025 | $0.78 est $0.58 | $14.65B est $13.56B | +1.7% |
| Apr 29, 2025 | $0.92 est $0.67 | $13.72B est $13.92B | +5.9% |
| Feb 4, 2025 | $0.63 est $0.47 | $17.76B est $17.35B | +0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Pfizer stock forecast and analyst price targets
Analysts’ average 12-month price target for Pfizer is $29.26, −5.0% from the last close, from 22 firms rating the stock in the last 90 days.
$29.26consensus 12-month target, −5.0% from the last close
Now $30.79Avg $29.26
Low $25High $36
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | UBS | $30 | −2.6% |
| Nov 4 | Morgan Stanley | $26 | −15.6% |
| Nov 4 | Citi | $30 | −2.6% |
| Nov 4 | Goldman Sachs | $28 | −9.1% |
| Nov 4 | BMO Capital | $35 | +13.7% |
−0.1%average 20-day move after past Neutral readings
+4.4%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Pfizer seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Pfizer averaged +4.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.8% | 3 of 5 |
| Next 10 trading days | +1.9% | 3 of 5 |
| Next 15 trading days | +4.9% | 3 of 5 |
| Next 20 trading days | +4.4% | 3 of 5 |
| Next 30 trading days | +5.9% | 3 of 5 |
For scale, PFE’s typical 20-trading-day move in either direction is about 4.5%.
Pfizer market cap and key statistics
Pfizer’s market cap is $175.5B, with a P/E ratio of 40.4 and revenue of $63.70B over the last twelve months.
Valuation
- Market cap
- $175.5B
- P/E ratio
- 40.4
- Forward P/E
- 10.5
- EPS, TTM
- $0.76
- Gekko Fair Value
- $32.11
Trading
- Volume
- 46.66M
- Avg volume, 20 days
- 31.54M
- 52-week high
- $31.06
- 52-week low
- $23.62
- Shares outstanding
- 5.70B
Financials
- Revenue, TTM
- $63.70B
- Profit margin
- 6.8%
- Return on equity
- 5%
- Quarterly earnings growth, YoY
- −10.1%
Risk and income
- Beta
- 0.30
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.5%
- Dividend yield
- 5.64%
Pfizer stock news this week
Coverage of Pfizer this week reads positive: 9 positive, 7 neutral and 1 negative headlines.
- Pfizer, Inc. (PFE) Stock ForecastsYahoo! Finance Canada, Nov 4
- Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% YieldSeeking Alpha, Nov 4
- United Therapeutics Pays $525 Million to Eliminate Pfizer Royalties on Ralinepagcitybiz, Nov 4
- United Therapeutics buys out Pfizer royalty for $525 millionInvesting.com, Nov 4
- United Therapeutics buys out Pfizer royalties linked to lung disease therapyTradingView, Nov 4
- Pfizer Just Raised Guidance. The Bigger Test Comes NextYahoo! Finance Canada, Nov 4
Pfizer peers
Pfizer’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
Pfizer stock FAQ
What is Pfizer’s market cap?
Pfizer’s market cap is $175.5B at the Nov 4, 2026 close of $30.79, with 5.70B shares outstanding. The shares trade on a P/E ratio of 40.4.
What is the Pfizer stock forecast?
The consensus analyst 12-month price target for Pfizer is $29.26, −5.0% from the last close. Of the 22 firms that rated the stock in the last 90 days, 8 rate it a buy, 13 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Pfizer stock overvalued or undervalued?
On Gekko’s estimate Pfizer is about fair value: the Nov 4, 2026 close of $30.79 is 4.1% below Gekko Fair Value of $32.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Pfizer report earnings next?
Pfizer is expected to report on Feb 2, 2027 (89 days away). Analysts expect earnings of $0.72 per share on revenue of $17.01B. Pfizer beat the earnings estimate in 8 of its last 8 reports, moving 1.7% on average across the report.
What is Pfizer’s 52-week high and low?
Pfizer’s 52-week high is $31.06 and its 52-week low is $23.62; it closed at $30.79 on Nov 4, 2026, +24.9% over the past year. Over the last five years the shares peaked at $61.71 on Dec 20, 2021.
Is Pfizer stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Pfizer the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.